Neuroblastoma is the most common extracranial solid tumour of infancy. Pathological activation of glucose consumption, glycolysis and glycolysis-activating Akt kinase occur frequently in neuroblastoma cells, and these changes correlate with poor prognosis of patients. Therefore, several inhibitors of glucose utilization and the Akt kinase activity are in preclinical trials as potential anti-cancer drugs. However, metabolic plasticity of cancer cells might undermine efficacy of this approach. In this work, we identified oxidative phosphorylation as compensatory mechanism preserving viability of neuroblastoma cells with inhibited glucose uptake/Akt kinase. It was oxidative phosphorylation that maintained intracellular level of ATP and proliferative capacity of these cells. The oxidative phosphorylation inhibitors (rotenone, tetrathiomolybdate) synergized with inhibitor of the Akt kinase/glucose uptake in down-regulation of both viability of neuroblastoma cells and clonogenic potential of cells forming neuroblastoma spheroids. Interestingly, tetrathiomolybdate acted as highly specific inhibitor of oxygen consumption and activator of lactate production in neuroblastoma cells, but not in normal fibroblasts and neuronal cells. Moreover, the reducing effect of tetrathiomolybdate on cell viability and the level of ATP in the cells with inhibited Akt kinase/glucose uptake was also selective for neuroblastoma cells. Therefore, efficient elimination of neuroblastoma cells requires inhibition of both glucose uptake/Akt kinase and oxidative phosphorylation activities. The use of tetrathiomolybdate as a mitochondrial inhibitor contributes to selectivity of this combined treatment, preferentially targeting neuroblastoma cells.

Center for Biological and Cellular Engineering International Clinical Research Center St Anne's University Hospital Brno Czech Republic

Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3: 203–16. PubMed

Spix C, Pastore G, Sankila R, et al Neuroblastoma incidence and survival in European children (1978‐1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006; 42: 2081–91. PubMed

Matthay KK, Reynolds CP, Seeger RC, et al Long‐term results for children with high‐risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13‐cis‐retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27: 1007–13. PubMed PMC

Aminzadeh S, Vidali S, Sperl W, et al Energy metabolism in neuroblastoma and Wilms tumor. Transl Pediatr. 2015; 4: 20–32. PubMed PMC

Komurov K, Tseng JT, Muller M, et al The glucose‐deprivation network counteracts lapatinib‐induced toxicity in resistant ErbB2‐positive breast cancer cells. Mol Syst Biol. 2012; 8: 596. PubMed PMC

Parmenter TJ, Kleinschmidt M, Kinross KM, et al Response of BRAF‐mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014; 4: 423–33. PubMed PMC

Gottschalk S, Anderson N, Hainz C, et al Imatinib (STI571)‐mediated changes in glucose metabolism in human leukemia BCR‐ABL‐positive cells. Clin Cancer Res. 2004; 10: 6661–8. PubMed

Elstrom RL, Bauer DE, Buzzai M, et al Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004; 64: 3892–9. PubMed

Yun J, Rago C, Cheong I, et al Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009; 325: 1555–9. PubMed PMC

Hagenbuchner J, Kuznetsov AV, Obexer P, et al BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene. 2013; 32: 4748–57. PubMed

Morscher RJ, Aminzadeh‐Gohari S, Feichtinger RG, et al Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1‐Nu Mouse Model. PLoS One. 2015; 10: e0129802. PubMed PMC

Hagenbuchner J, Kiechl‐Kohlendorfer U, Obexer P, et al BIRC5/Survivin as a target for glycolysis inhibition in high‐stage neuroblastoma. Oncogene. 2016; 35: 2052–61. PubMed

Vadlakonda L, Dash A, Pasupuleti M, et al The Paradox of Akt‐mTOR Interactions. Front Oncol. 2013; 3: 165. PubMed PMC

Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005; 9: 59–71. PubMed PMC

Toker A, Newton AC. Cellular signaling: pivoting around PDK‐1. Cell. 2000; 103: 185–8. PubMed

Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet. 2005; 14 Spec No. 2: R251–8. PubMed

Sarbassov DD, Guertin DA, Ali SM, et al Phosphorylation and regulation of Akt/PKB by the rictor‐mTOR complex. Science. 2005; 307: 1098–101. PubMed

Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129: 1261–74. PubMed PMC

Kumar A, Lawrence JC Jr, Jung DY, et al Fat cell‐specific ablation of rictor in mice impairs insulin‐regulated fat cell and whole‐body glucose and lipid metabolism. Diabetes. 2010; 59: 1397–406. PubMed PMC

Cho H, Thorvaldsen JL, Chu Q, et al Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001; 276: 38349–52. PubMed

Cho H, Mu J, Kim JK, et al Insulin resistance and a diabetes mellitus‐like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001; 292: 1728–31. PubMed

Tschopp O, Yang ZZ, Brodbeck D, et al Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005; 132: 2943–54. PubMed

Sun W, Modak S. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther. 2012; 5: 21–9. PubMed PMC

Sartelet H, Oligny LL, Vassal G. AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther. 2008; 8: 757–69. PubMed

Yi YW, Hong W, Kang HJ, et al Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple‐negative breast cancer cells. J Cell Mol Med. 2013; 17: 648–56. PubMed PMC

Luo M, Liu Q, He M, et al Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells. J Cell Mol Med. 2017; 21: 46–57. PubMed PMC

Wang B, Shi L, Sun X, et al Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway. J Cell Mol Med. 2016; 20: 920–9. PubMed PMC

Barnett SF, Defeo‐Jones D, Fu S, et al Identification and characterization of pleckstrin‐homology‐domain‐dependent and isoenzyme‐specific Akt inhibitors. Biochem J. 2005; 385: 399–408. PubMed PMC

Tan SX, Ng Y, James DE. Akt inhibitors reduce glucose uptake independently of their effects on Akt. Biochem J. 2010; 432: 191–7. PubMed

Viale A, Corti D, Draetta GF. Tumors and Mitochondrial Respiration: a Neglected Connection. Cancer Res. 2015; 75: 3685–6. PubMed

Viale A, Pettazzoni P, Lyssiotis CA, et al Oncogene ablation‐resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514: 628–32. PubMed PMC

Feichtinger RG, Zimmermann F, Mayr JA, et al Low aerobic mitochondrial energy metabolism in poorly‐ or undifferentiated neuroblastoma. BMC Cancer. 2010; 10: 149. PubMed PMC

Cornelissen J, Wanders RJ, Van den Bogert C, et al Meta‐iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK‐N‐BE(2c). Eur J Cancer. 1995; 31A: 582–6. PubMed

Sherer TB, Betarbet R, Testa CM, et al Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003; 23: 10756–64. PubMed PMC

Brodeur GM, Seeger RC, Schwab M, et al Amplification of N‐myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224: 1121–4. PubMed

Smith DJ, Cossins LR, Hatzinisiriou I, et al Lack of correlation between MYCN expression and the Warburg effect in neuroblastoma cell lines. BMC Cancer. 2008; 8: 259. PubMed PMC

Bartova E, Vecera J, Krejci J, et al The level and distribution pattern of HP1beta in the embryonic brain correspond to those of H3K9me1/me2 but not of H3K9me3. Histochem Cell Biol. 2016; 145: 447–61. PubMed

Navratilova J, Hankeova T, Benes P, et al Low‐glucose conditions of tumor microenvironment enhance cytotoxicity of tetrathiomolybdate to neuroblastoma cells. Nutr Cancer. 2013; 65: 702–10. PubMed

Franken NA, Rodermond HM, Stap J, et al Clonogenic assay of cells in vitro . Nat Protoc. 2006; 1: 2315–9. PubMed

Ross DD, Joneckis CC, Ordonez JV, et al Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. Cancer Res. 1989; 49: 3776–82. PubMed

Robey RB, Hay N. Is Akt the “Warburg kinase”?‐Akt‐energy metabolism interactions and oncogenesis. Semin Cancer Biol. 2009; 19: 25–31. PubMed PMC

Opel D, Poremba C, Simon T, et al Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 2007; 67: 735–45. PubMed

Cross DA, Alessi DR, Cohen P, et al Inhibition of glycogen synthase kinase‐3 by insulin mediated by protein kinase B. Nature. 1995; 378: 785–9. PubMed

Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18: 1926–45. PubMed

Chou TC. Drug combination studies and their synergy quantification using the Chou‐Talalay method. Cancer Res. 2010; 70: 440–6. PubMed

Sonveaux P, Vegran F, Schroeder T, et al Targeting lactate‐fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008; 118: 3930–42. PubMed PMC

Pelicano H, Xu RH, Du M, et al Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox‐mediated mechanism. J Cell Biol. 2006; 175: 913–23. PubMed PMC

Chen CH, Kiyan V, Zhylkibayev AA, et al Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP‐dependent mechanism. J Biol Chem. 2013; 288: 27019–30. PubMed PMC

Smolkova K, Plecita‐Hlavata L, Bellance N, et al Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol. 2011; 43: 950–68. PubMed

Haq R, Shoag J, Andreu‐Perez P, et al Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 2013; 23: 302–15. PubMed PMC

Wolf A, Agnihotri S, Micallef J, et al Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011; 208: 313–26. PubMed PMC

Alvarez‐Calderon F, Gregory MA, Pham‐Danis C, et al Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2015; 21: 1360–72. PubMed PMC

Goo CK, Lim HY, Ho QS, et al PTEN/Akt signaling controls mitochondrial respiratory capacity through 4E‐BP1. PLoS One. 2012; 7: e45806. PubMed PMC

Swerdlow RH, Lezi E, Aires D, et al Glycolysis‐respiration relationships in a neuroblastoma cell line. Biochim Biophys Acta. 2013; 1830: 2891–8. PubMed PMC

Klepinin A, Chekulayev V, Timohhina N, et al Comparative analysis of some aspects of mitochondrial metabolism in differentiated and undifferentiated neuroblastoma cells. J Bioenerg Biomembr. 2014; 46: 17–31. PubMed

Bhat TA, Kumar S, Chaudhary AK, et al Restoration of mitochondria function as a target for cancer therapy. Drug Discov Today. 2015; 20: 635–43. PubMed PMC

Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013; 4: e532. PubMed PMC

Bonnet S, Archer SL, Allalunis‐Turner J, et al A mitochondria‐K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11: 37–51. PubMed

Kim KK, Abelman S, Yano N, et al Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia‐inducible factor‐1alpha in cancer cells. Sci Rep. 2015; 5: 14296. PubMed PMC

Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med. 2003; 7: 11–20. PubMed PMC

Kumar HR, Zhong X, Hoelz DJ, et al Three‐dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids. Pediatr Surg Int. 2008; 24: 1229–34. PubMed PMC

Choo AY, Kim SG, Vander Heiden MG, et al Glucose addiction of TSC null cells is caused by failed mTORC1‐dependent balancing of metabolic demand with supply. Mol Cell. 2010; 38: 487–99. PubMed PMC

Alvarez HM, Xue Y, Robinson CD, et al Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science. 2010; 327: 331–4. PubMed PMC

Ishida S, Andreux P, Poitry‐Yamate C, et al Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci USA. 2013; 110: 19507–12. PubMed PMC

Lee YM, Chang WC, Ma WL. Hypothesis: solid tumours behave as systemic metabolic dictators. J Cell Mol Med. 2016; 20: 1076–85. PubMed PMC

Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009; 35: 32–46. PubMed

Wang J, Luo C, Shan C, et al Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. Nat Chem. 2015; 7: 968–79. PubMed PMC

Matoba S, Kang JG, Patino WD, et al p53 regulates mitochondrial respiration. Science. 2006; 312: 1650–3. PubMed

Jaksch M, Paret C, Stucka R, et al Cytochrome c oxidase deficiency due to mutations in SCO2, encoding a mitochondrial copper‐binding protein, is rescued by copper in human myoblasts. Hum Mol Genet. 2001; 10: 3025–35. PubMed

Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells

Dual specificity phosphatase 7 drives the formation of cardiac mesoderm in mouse embryonic stem cells

Lactic Acidosis Interferes With Toxicity of Perifosine to Colorectal Cancer Spheroids: Multimodal Imaging Analysis